Evoke Pharma Surges on Notice of Patent Allowance for Gimoti

Dow Jones

Jul 10, 2025

By Josh Beckerman

Evoke Pharma shares surged after the company received a notice of allowance for a U.S. patent application for Gimoti extending Orange Book listings to 2036.

The stock was up 154% to $6.75 Wednesday, with an intraday high of $9.88. The stock is up over 50% this year. Volume was roughly 124 million shares as of early-afternoon trading, compared with a 90-day average of about 19,000.

Gimoti is a nasal spray for relief of symptoms associated with acute and recurrent diabetic gastroparesis.

Evoke said the allowed application is a continuation of U.S. Patent No. 11,517,545, and that it further expands Evoke's intellectual property estate around intranasal metoclopramide. The company said it has filed another U.S. continuation application to pursue additional claims.

Write to Josh Beckerman at josh.beckerman@wsj.com

(END) Dow Jones Newswires

July 09, 2025 13:46 ET (17:46 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2550657544"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2550657544\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2550657544?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-10 01:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2550657544","market":"hk","top_or_hot":-1,"title":"Evoke Pharma Surges on Notice of Patent Allowance for Gimoti","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Josh Beckerman \n</p>\n<pre>\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/EVOK\">Evoke Pharma</a> shares surged after the company received a notice of allowance for a U.S. patent application for Gimoti extending <a href=\"https://laohu8.com/S/FNCTF\">Orange</a> Book listings to 2036. \n</p>\n<p>\n  The stock was up 154% to $6.75 Wednesday, with an intraday high of $9.88. The stock is up over 50% this year. Volume was roughly 124 million shares as of early-afternoon trading, compared with a 90-day average of about 19,000. \n</p>\n<p>\n  Gimoti is a nasal spray for relief of symptoms associated with acute and recurrent diabetic gastroparesis. \n</p>\n<p>\n  Evoke said the allowed application is a continuation of U.S. Patent No. 11,517,545, and that it further expands Evoke's intellectual property estate around intranasal metoclopramide. The company said it has filed another U.S. continuation application to pursue additional claims. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Josh Beckerman at josh.beckerman@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 09, 2025 13:46 ET (17:46 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Evoke Pharma Surges on Notice of Patent Allowance for Gimoti</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEvoke Pharma Surges on Notice of Patent Allowance for Gimoti\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-07-10 01:46</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Josh Beckerman \n</p>\n<pre>\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/EVOK\">Evoke Pharma</a> shares surged after the company received a notice of allowance for a U.S. patent application for Gimoti extending <a href=\"https://laohu8.com/S/FNCTF\">Orange</a> Book listings to 2036. \n</p>\n<p>\n  The stock was up 154% to $6.75 Wednesday, with an intraday high of $9.88. The stock is up over 50% this year. Volume was roughly 124 million shares as of early-afternoon trading, compared with a 90-day average of about 19,000. \n</p>\n<p>\n  Gimoti is a nasal spray for relief of symptoms associated with acute and recurrent diabetic gastroparesis. \n</p>\n<p>\n  Evoke said the allowed application is a continuation of U.S. Patent No. 11,517,545, and that it further expands Evoke's intellectual property estate around intranasal metoclopramide. The company said it has filed another U.S. continuation application to pursue additional claims. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Josh Beckerman at josh.beckerman@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 09, 2025 13:46 ET (17:46 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"EVOK","symbol_name":"Evoke Pharma Inc.","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2550657544","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2550657544","pubTimestamp":1752083160,"columns":[{"name":"Product Release","id":31,"label_key":"productRelease"}],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Evoke Pharma shares surged after the company received a notice of allowance for a U.S. patent application for Gimoti extending Orange Book listings to 2036.The stock was up 154% to $6.75 Wednesday, with an intraday high of $9.88. The stock is up over 50% this year. Volume was roughly 124 million shares as of early-afternoon trading, compared with a 90-day average of about 19,000.Gimoti is a nasal spray for relief of symptoms associated with acute and recurrent diabetic gastroparesis.Evoke said the allowed application is a continuation of U.S. Patent No. 11,517,545, and that it further expands Evoke's intellectual property estate around intranasal metoclopramide. The company said it has filed another U.S. continuation application to pursue additional claims.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"EVOK":"Evoke Pharma Inc.","BK4007":"制药"},"translate_title":"Evoke Pharma因Gimoti专利许可通知而股价飙升","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EVOK":1},"content_text":"By Josh Beckerman \n\n\n \n\n\nEvoke Pharma shares surged after the company received a notice of allowance for a U.S. patent application for Gimoti extending Orange Book listings to 2036. \n\n\n  The stock was up 154% to $6.75 Wednesday, with an intraday high of $9.88. The stock is up over 50% this year. Volume was roughly 124 million shares as of early-afternoon trading, compared with a 90-day average of about 19,000. \n\n\n  Gimoti is a nasal spray for relief of symptoms associated with acute and recurrent diabetic gastroparesis. \n\n\n  Evoke said the allowed application is a continuation of U.S. Patent No. 11,517,545, and that it further expands Evoke's intellectual property estate around intranasal metoclopramide. The company said it has filed another U.S. continuation application to pursue additional claims. \n\n\n \n\n\n  Write to Josh Beckerman at josh.beckerman@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  July 09, 2025 13:46 ET (17:46 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}